{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:07:26Z","timestamp":1765728446239},"reference-count":31,"publisher":"AACN Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:p>Hyponatremia (serum sodium &amp;lt;135 mEq\/L) is the most common electrolyte disorder. The severity of symptoms is related to how rapidly the condition develops and the degree of cerebral edema that results from the low serum level of sodium. Hypertonic saline and the new vasopressin receptor antagonists are highly effective treatments for severe symptomatic hyponatremia, yet they can result in severe neurological complications if sodium levels are restored too quickly. Hyponatremia is classified as hypovolemic, euvolemic, and hypervolemic. Treatments include administration of high-risk medications and fluid restriction to restore fluid and electrolyte balance and relieve cerebral effects. Nursing care to ensure safe outcomes involves multidisciplinary collaboration, close monitoring of serum sodium levels and intake and output, and assessment for neurological changes.<\/jats:p>","DOI":"10.4037\/ccn2012173","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T03:15:52Z","timestamp":1338520552000},"page":"e11-e20","source":"Crossref","is-referenced-by-count":3,"title":["Hyponatremia Caused by Polydipsia"],"prefix":"10.4037","volume":"32","author":[{"given":"Lyne","family":"Chamberlain","sequence":"first","affiliation":[{"name":"Lyne Chamberlain is a Clinical nurse specialist in cardiology at Dr P. Phillips Hospital, Orlando, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"11A","key":"2019112601291113400_b1-0320e11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","article-title":"Hyponatremia treatment guidelines 2007: expert panel recommendations","volume":"120","author":"Verbalis","year":"2007","journal-title":"Am J Med."},{"issue":"3","key":"2019112601291113400_b2-0320e11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.semnephrol.2009.03.004","article-title":"Epidemiology of hyponatremia","volume":"29","author":"Upadhyay","year":"2009","journal-title":"Semin Nephrol."},{"key":"2019112601291113400_b3-0320e11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.amjmed.2006.09.031","article-title":"Hyponatremia: clinical diagnosis and management","volume":"120","author":"Lien","year":"2007","journal-title":"Am J Med."},{"issue":"10","key":"2019112601291113400_b4-0320e11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2169\/internalmedicine.47.0918","article-title":"Treatment of hyponatremia","volume":"47","author":"Gross","year":"2008","journal-title":"Intern Med."},{"issue":"5","key":"2019112601291113400_b5-0320e11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2006.01.020","article-title":"Vasopressin excess and hyponatremia","volume":"47","author":"Pham","year":"2006","journal-title":"Am J Kidney Dis."},{"issue":"21","key":"2019112601291113400_b6-0320e11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med."},{"key":"2019112601291113400_b7-0320e11","first-page":"1067","article-title":"Management of persons with problems of the pituitary, thyroid, parathyroid, and adrenal glands","volume-title":"Medical-Surgical Nursing: Concepts and Clinical Practice","author":"Romeo","year":"1995","edition":"6th ed"},{"issue":"6","key":"2019112601291113400_b8-0320e11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MAJ.0b013e3181d3cd78","article-title":"Osmotic demyelination syndrome","volume":"339","author":"King","year":"2010","journal-title":"Am J Med Sci."},{"issue":"2","key":"2019112601291113400_b9-0320e11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clinthera.2007.02.004","article-title":"Recognition and treatment of hyponatremia in acutely ill hospitalized patients","volume":"29","author":"Patel","year":"2007","journal-title":"Clin Ther."},{"key":"2019112601291113400_b10-0320e11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ecl.2006.09.011","article-title":"Disorders of body water homeostasis in critical illness","volume":"35","author":"Adler","year":"2006","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2019112601291113400_b11-0320e11","first-page":"841","article-title":"Electrolyte emergencies","volume-title":"AACN Advanced Critical Care Nursing","author":"Day","year":"2009"},{"key":"2019112601291113400_b12-0320e11","first-page":"2387","article-title":"Management of hyponatremia","volume":"69","author":"Goh","year":"2004","journal-title":"Am Fam Physician."},{"issue":"2","key":"2019112601291113400_b13-0320e11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11319070-000000000-00000","article-title":"Antipsychotic-induced hyponatraemia: a systematic review of the published evidence","volume":"33","author":"Meulendijks","year":"2010","journal-title":"Drug Saf."},{"issue":"3","key":"2019112601291113400_b14-0320e11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11920-007-0025-7","article-title":"Psychogenic polydipsia review: etiology, differential, and treatment","volume":"9","author":"Dundas","year":"2007","journal-title":"Curr Psychiatry Rep."},{"key":"2019112601291113400_b15-0320e11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccc.2008.05.004","article-title":"Medical complications of psychiatric treatment","volume":"24","author":"Smith","year":"2008","journal-title":"Crit Care Clin."},{"key":"2019112601291113400_b16-0320e11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2146\/060101","article-title":"New agents for managing hyponatremia in hospitalized patients","volume":"64","author":"Munger","year":"2007","journal-title":"Am J Health Syst Pharm."},{"key":"2019112601291113400_b17-0320e11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10557-009-6180-9","article-title":"Hyponatremia in heart failure: the role of arginine vasopressin and diuretics","volume":"23","author":"Rosner","year":"2009","journal-title":"Cardiovasc Drugs Ther."},{"issue":"6","key":"2019112601291113400_b18-0320e11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00003495-200767060-00002","article-title":"Therapeutic potential of vasopressin receptor antagonists","volume":"67","author":"Ali","year":"2007","journal-title":"Drugs."},{"key":"2019112601291113400_b19-0320e11","unstructured":"Astellas Pharmaceuticals. Vaprisol (conivaptan) prescribing information [package insert]. http:\/\/www.astellas.us\/docs\/vaprisol.pdf. Revised February 2012. Accessed March 15, 2012."},{"issue":"10","key":"2019112601291113400_b20-0320e11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3949\/ccjm.77a.08051","article-title":"Management of hyponatremia: providing treatment and avoiding harm","volume":"77","author":"Vaidya","year":"2010","journal-title":"Cleve Clin J Med."},{"key":"2019112601291113400_b21-0320e11","unstructured":"SAMSCA (tolvaptan). SAMSCA Web site. http:\/\/www.samsca.com. Accessed March 15, 2012."},{"key":"2019112601291113400_b22-0320e11","first-page":"83","article-title":"Conivaptan: evidence supporting its therapeutic use in hyponatremia","volume":"4","author":"Li-Ng","year":"2010","journal-title":"Core Evid."},{"issue":"1","key":"2019112601291113400_b23-0320e11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"Efficacy and safety of oral conivaptan, a vasopressin receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"337","author":"Annane","year":"2009","journal-title":"Am J Med Sci."},{"key":"2019112601291113400_b24-0320e11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","article-title":"Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial","volume":"48","author":"Gines","year":"2008","journal-title":"Hepatology."},{"issue":"6","key":"2019112601291113400_b25-0320e11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a VIA\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"2019112601291113400_b26-0320e11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol."},{"key":"2019112601291113400_b27-0320e11","unstructured":"Baylor University Medical Center. Cytochrome P450 drug metabolism. 2000, October. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1312247\/table\/TU1\/. Accessed February 23, 2010,"},{"key":"2019112601291113400_b28-0320e11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000441-200307000-00004","article-title":"Treatment of symptomatic hyponatremia","volume":"326","author":"Decaux","year":"2003","journal-title":"Am J Med Sci."},{"key":"2019112601291113400_b29-0320e11","unstructured":"The Joint Commission. 2012 National patient safety goals. www.jointcommisssion.org\/standards_information\/npsgs.aspx. Accessed March 24, 2012."},{"key":"2019112601291113400_b30-0320e11","unstructured":"MedlinePlus Medical Encyclopedia. Hyponatremia. http:\/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/000394.htm. Updated May 29, 2011. Accessed March 15, 2012."},{"issue":"7","key":"2019112601291113400_b31-0320e11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00003246-199907000-00022","article-title":"Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients","volume":"27","author":"Riker","year":"1999","journal-title":"Crit Care Med."}],"container-title":["Critical Care Nurse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/32\/3\/e11\/111833\/e11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/32\/3\/e11\/111833\/e11.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T01:29:26Z","timestamp":1574731766000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/ccnonline\/article\/32\/3\/e11\/4456\/Hyponatremia-Caused-by-Polydipsia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.4037\/ccn2012173","relation":{},"ISSN":["0279-5442","1940-8250"],"issn-type":[{"value":"0279-5442","type":"print"},{"value":"1940-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}